ENYO Pharma is a biotechnology startup based in Brussels, Belgium, focused on developing innovative therapies for viral infections and liver diseases. The company leverages its proprietary discovery engine to identify and develop new drug candidates. ENYO Pharma's primary areas of research include chronic hepatitis B, non-alcoholic steatohepatitis (NASH), and COVID-19, among other viral threats.

The company serves a diverse range of clients, including healthcare providers, pharmaceutical companies, and research institutions. ENYO Pharma operates in the biopharmaceutical market, which involves the development and commercialization of drugs derived from biological sources.

ENYO Pharma's business model revolves around the research and development (R&D) of novel therapeutics. The company advances its drug candidates through various stages of clinical trials, aiming to demonstrate their safety and efficacy. Once a drug candidate shows promise, ENYO Pharma can either partner with larger pharmaceutical companies for further development and commercialization or bring the product to market independently.

The company generates revenue through multiple streams. These include licensing agreements, where other companies pay for the rights to develop and market ENYO Pharma's drug candidates. Additionally, ENYO Pharma may receive milestone payments as its drug candidates progress through clinical trials and regulatory approvals. The company also benefits from funding and grants, such as those from the European Union, to support its research initiatives.

ENYO Pharma's executive team comprises experienced leaders from the pharmaceutical industry and scientific experts in biology and drug development. This combination of expertise is crucial for driving the company's innovative approach and advancing its pipeline of drug candidates.

Keywords: biotechnology, drug development, viral infections, liver diseases, hepatitis B, NASH, COVID-19, clinical trials, licensing agreements, pharmaceutical partnerships.